Incyte Gains European Commission Approval for Povofortay
Incyte said the European Commission has approved Povofortay (povorcitinib) for adults with moderate to severe hidradenitis suppurativa, a chronic skin disease. The company described the clearance as making the drug the first once-daily oral treatment available in the EU for the condition.
Incyte framed the approval as a new growth opportunity, saying the decision is supported by strong clinical results for the therapy. Hidradenitis suppurativa has had limited oral treatment options in Europe, according to the company's announcement.
The approval adds a commercial product in Europe for a company that reported revenue of 5.14 billion USD and net income of 1.29 billion USD in fiscal 2025. Incyte's next earnings date is scheduled for Feb 9, 2027.